PMID: 2470352Jan 1, 1988Paper

Cardiac and side effects of prostaglandin F2 alpha in patients with extrasystoles

Biomedica Biochimica Acta
W SziegoleitH Hofmann


In 17 patients with cardiac extrasystoles, prostaglandin (PG) F2a (= alpha) administered intravenously at consecutive infusion rates of 25 to 100 micrograms/min showed the following effects in a dose-dependent manner: prolongation of total electromechanical systole, pre-ejection period, and left ventricular ejection time, indicating a negative inotropic activity, increase in systolic and diastolic blood pressure, and incidence of side effects. An additional 2 patients were excluded from the uniform evaluation because the PGF2a dosage was changed owing to a clear antiarrhythmic action in one and serious side effects in the other. The results supplement clinical-pharmacological findings with PGF2a.

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.